drugset / Trial / NCT00035893
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA \< 50 copies/ml (PCR) and CD4 levels \> 400.
Timeline
- Start
- 2001-05
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rintatolimod | Oligonucleotide (other) | 200 mg | Intravenous |
| Subject | Rintatolimod | Oligonucleotide (other) | 400 mg | Intravenous |